The upside case is a turnaround, not a moonshot. Stem does not need to dominate a huge market; it mainly needs to survive the financing squeeze, keep growing recurring software and services faster than legacy revenue shrinks, and earn a cleaner quality label from investors. If that happens, even a modest enterprise
rerating can translate into strong equity returns because today’s stock is depressed by leverage and skepticism.